Drug Protects Heart in Children Receiving Common Chemotherapy
Children treated with an anthracycline have more than a threefold increased risk of cardiac death 30 years after treatment compared with their untreated peers.
The drug dexrazoxane, which can protect heart tissue from the oxidative damage caused by doxorubicin and other anthracycline drugs, significantly reduced the occurrence of long-term heart damage in children undergoing treatment for high-risk acute lymphoblastic leukemia (ALL).
Enhancing the lives of families and children by providing education and advocacy, emotional and practical support, and most of all... HOPE....because kids can't fight cancer alone!
No comments:
Post a Comment